Want to see TSE:VPT full AI Analyst Report?
VPT Stock Chart & Stats
C$0.12
C$0.00(0.00%)
At close: 4:00 PM EST
C$0.12
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$0.08 - C$0.19
Previous CloseN/A
Volume32.00K
Average Volume (3M)106.78K
Market Cap
C$21.18M
Enterprise ValueC$25.07M
Total Cash (Recent Filing)C$55.39K
Total Debt (Recent Filing)C$2.60M
Price to Earnings (P/E)―
Beta-0.60
Next Earnings
Aug 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding192,577,940
10 Day Avg. Volume85,718
30 Day Avg. Volume106,775
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)-5.63
Price to Sales (P/S)128.71
P/FCF Ratio-14.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Revenue AccelerationA ~245% YoY revenue acceleration signals clear market traction and product acceptance. Durable top-line momentum provides a foundation to achieve scale, attract partners or funding, and gives management room to pursue unit economics improvements that can convert growth into sustainable earnings over months.
High And Improving Gross MarginsSustained high gross margins (~66% in 2025) indicate favorable unit economics and product pricing power. This structural margin advantage means incremental revenue can flow to the bottom line more readily if operating expenses are controlled, supporting a credible path to profitability as scale increases.
Reduced Cash Burn Year-over-yearA meaningful reduction in operating cash burn from -$3.4M to -$1.6M demonstrates management progress on cost control or working capital. Durable reductions in cash outflows extend runway, lower near‑term funding urgency, and improve the company’s ability to execute strategic initiatives over the next several months.
Bears Say
Deeply Negative EquityDeeply negative equity (~-$4.1M) reflects cumulative losses that impair solvency and financial flexibility. Structurally weak equity limits access to traditional financing, increases reliance on dilutive capital or expensive debt, and constrains the company’s ability to invest in long-term growth initiatives.
Persistent Operating Cash BurnConsistent negative operating cash flow and deteriorating free cash flow (FCF roughly matches net loss) indicate losses are manifesting as real cash outflows. Over the medium term this creates structural funding needs and raises probability of dilutive financing or restrictive covenants that impair strategic flexibility.
Large Operating Losses And Negative MarginsVery large negative net margin and EBIT losses show the business has not attained operating leverage despite revenue growth. Structural mismatch between cost base and revenue scale raises risk that revenue growth alone won’t translate to sustainable profits without a durable change to the operating model or expense structure.
VPT FAQ
What was VentriPoint Diagnostics Ltd’s price range in the past 12 months?
VentriPoint Diagnostics Ltd lowest stock price was C$0.08 and its highest was C$0.19 in the past 12 months.
What is VentriPoint Diagnostics Ltd’s market cap?
VentriPoint Diagnostics Ltd’s market cap is C$21.18M.
When is VentriPoint Diagnostics Ltd’s upcoming earnings report date?
VentriPoint Diagnostics Ltd’s upcoming earnings report date is Aug 28, 2026 which is in 57 days.
How were VentriPoint Diagnostics Ltd’s earnings last quarter?
Currently, no data Available
Is VentriPoint Diagnostics Ltd overvalued?
According to Wall Street analysts VentriPoint Diagnostics Ltd’s price is currently Overvalued.
Does VentriPoint Diagnostics Ltd pay dividends?
VentriPoint Diagnostics Ltd does not currently pay dividends.
What is VentriPoint Diagnostics Ltd’s EPS estimate?
VentriPoint Diagnostics Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does VentriPoint Diagnostics Ltd have?
VentriPoint Diagnostics Ltd has 192,577,940 shares outstanding.
What happened to VentriPoint Diagnostics Ltd’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of VentriPoint Diagnostics Ltd?
Currently, no hedge funds are holding shares in TSE:VPT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
VentriPoint Diagnostics Ltd
VentriPoint Diagnostics Ltd. is a medical technology company focused on developing and commercializing diagnostic tools worldwide. These innovative solutions are designed to monitor individuals afflicted with cardiovascular disease. At the core of their offerings is the Ventripoint Medical System (VMS), an advanced medical imaging platform. The VMS generates precise three-dimensional models of the heart's chambers, providing crucial volumetric and functional measurements. This system is further enhanced by its VMS+ software, which processes echocardiogram and magnetic resonance imaging (MRI) data to construct these 3D models. The VMS+ software ensures highly reproducible and accurate quantification of heart chamber volumes and ejection fraction. Beyond its current flagship system, VentriPoint Diagnostics is actively expanding its portfolio with a suite of specialized applications. These applications target various cardiac conditions and imaging techniques, including congenital heart disease, pulmonary hypertension, cardiotoxicity in oncology patients, and heart complications stemming from Covid-19. Founded in 2004, the company operates from its headquarters in Toronto, Canada.
Technical Analysis
Options Prices
Currently, No data available
---